Mereo BioPharma Group Analyst Ratings
Mereo BioPharma Group Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/08/2023 | 249.65% | Needham | → $5 | Reiterates | Buy → Buy |
| 08/23/2023 | 249.65% | Needham | → $5 | Reiterates | Buy → Buy |
| 06/06/2023 | 249.65% | Needham | → $5 | Reiterates | Buy → Buy |
| 05/26/2023 | 249.65% | Needham | → $5 | Reiterates | Buy → Buy |
| 04/21/2023 | 249.65% | Needham | → $5 | Reiterates | → Buy |
| 03/30/2023 | 249.65% | Needham | → $5 | Reiterates | → Buy |
| 11/10/2022 | 179.72% | SVB Leerink | $8 → $4 | Maintains | Outperform |
| 08/12/2022 | 179.72% | Cantor Fitzgerald | → $4 | Initiates Coverage On | → Overweight |
| 06/06/2022 | 249.65% | Needham | $10 → $5 | Maintains | Buy |
| 05/05/2021 | 599.3% | BTIG | → $10 | Initiates Coverage On | → Buy |
| 04/05/2021 | 599.3% | Needham | → $10 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 09/08/2023 | 249.65% | 李約瑟 | →$5 | 重申 | 購買→購買 |
| 2023/08/23 | 249.65% | 李約瑟 | →$5 | 重申 | 購買→購買 |
| 06/06/2023 | 249.65% | 李約瑟 | →$5 | 重申 | 購買→購買 |
| 2023年05月26日 | 249.65% | 李約瑟 | →$5 | 重申 | 購買→購買 |
| 04/21/2023 | 249.65% | 李約瑟 | →$5 | 重申 | →購買 |
| 03/30/2023 | 249.65% | 李約瑟 | →$5 | 重申 | →購買 |
| 2022年11月10日 | 179.72% | SVB Leerink | $8→$4 | 維護 | 跑贏大盤 |
| 2022年08月12日 | 179.72% | 康託·菲茨傑拉德 | →$4 | 開始承保 | →超重 |
| 06/06/2022 | 249.65% | 李約瑟 | $10→$5 | 維護 | 買 |
| 05/05/2021 | 599.3% | BTIG | →$10 | 開始承保 | →購買 |
| 04/05/2021 | 599.3% | 李約瑟 | →$10 | 開始承保 | →購買 |
What is the target price for Mereo BioPharma Group (MREO)?
Mereo BioPharma Group(MREO)的目標價是多少？
The latest price target for Mereo BioPharma Group (NASDAQ: MREO) was reported by Needham on September 8, 2023. The analyst firm set a price target for $5.00 expecting MREO to rise to within 12 months (a possible 249.65% upside). 7 analyst firms have reported ratings in the last year.
李約瑟於2023年9月8日報道了Mereo BioPharma Group(納斯達克：MREO)的最新目標價。這家分析公司將目標價定為5美元，預計MREO將在12個月內升至(可能上漲249.65)。去年有7家分析公司公佈了評級。
What is the most recent analyst rating for Mereo BioPharma Group (MREO)?
Mereo BioPharma Group(MREO)最近的分析師評級是多少？
The latest analyst rating for Mereo BioPharma Group (NASDAQ: MREO) was provided by Needham, and Mereo BioPharma Group reiterated their buy rating.
Mereo BioPharma Group(納斯達克代碼：MREO)的最新分析師評級由Needham提供，Mereo BioPharma Group重申其買入評級。
When is the next analyst rating going to be posted or updated for Mereo BioPharma Group (MREO)?
Mereo BioPharma Group(MREO)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Mereo BioPharma Group, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Mereo BioPharma Group was filed on September 8, 2023 so you should expect the next rating to be made available sometime around September 8, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公開財務報表，與Mereo BioPharma Group的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Mereo BioPharma Group的上一次評級是在2023年9月8日提交的，所以你應該預計下一次評級將在2024年9月8日左右提供。
Is the Analyst Rating Mereo BioPharma Group (MREO) correct?
分析師對Mereo BioPharma Group(MREO)的評級正確嗎？
While ratings are subjective and will change, the latest Mereo BioPharma Group (MREO) rating was a reiterated with a price target of $0.00 to $5.00. The current price Mereo BioPharma Group (MREO) is trading at is $1.43, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Mereo BioPharma Group(MREO)評級被重申，目標價在0.00美元至5.00美元之間。Mereo BioPharma Group(MREO)目前的交易價格為1.43美元，在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。